-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Overview of China's Hospital Drug Market In MAT2022Q1, the total sales of China's hospital drug market reached 976 Bn, a year-on-year increase of
From a quarterly perspective, the scale of the hospital market has declined in the past two quarte.
In 2022Q1, the national hospital drug market sales fell by 4% year-on-ye.
(Statistical caliber: Represents China’s second-level and above public hospitals, calculated at the hospital purchase price, the same below; MAT (Moving Annual Total): represents the sum of the indicators rolling forward one year from the current month; Bn: represents one billion) Figure 1 National -Hospital Drug Market - Sales Scale Secondary Hospitals vs Tertiary Hospitals: Sales of secondary and tertiary hospitals in 2022Q1 both declined year-on-year , and the structure remains stable; the sales of tertiary hospitals in 2022Q1 exceeded 157 .
Both secondary and tertiary hospitals saw a decline in sales in the quarter, with year-on-year growth rates of -4% and -5%, respective.
Figure 2 National - secondary & tertiary hospitals - sales proportion trend and sales growth rate (%) Chemical drugs (including biological products) VS Chinese patent medicines: The proportion of Chinese patent medicines has steadily increased, and 2022Q1 showed positive growth due to the attributes of traditional Chinese and Western medicines Look, the sales scale of chemical drugs (including biological products) has continued to decline in the past two quarters, and the year-on-year growth rate of sales in 2022Q1 is -
Different from chemical drugs, under the background of the state's vigorous support for the high-quality development of the Chinese medicine industry, the sales scale of Chinese patent medicines continued to increase, and this quarter maintained a positive year-on-year growth (+6.
Figure 3 National chemical drugs (including biological products) & Chinese patent medicines - sales ratio trend and year-on-year growth rate (%) Regional performance of hospital drug market: Guangdong Province ranks first in weight, Inner Mongolia and Hubei have outstanding growth, and the scale is double From a regional perspective, the hospital drug market in Guangdong Province ranks first in terms of scale, and the growth rate is slightly lower than the national level (4% vs 6%); Inner Mongolia and Hubei Province MAT2022Q1 sales increased rapidly, with double-digit growth year-on-ye.
Among the 30 provinces and cities, the hospital market in seven provinces, Jiangsu, Zhejiang, Heilongjiang, Yunnan, Guizhou, Gansu and Hainan, has shru.
Figure 4 National-Hospital Drug Market-Scale and Growth Rate of 30 Provinces and Cities (MAT2022Q1)
From a quarterly perspective, the scale of the hospital market has declined in the past two quarte.
In 2022Q1, the national hospital drug market sales fell by 4% year-on-ye.
(Statistical caliber: Represents China’s second-level and above public hospitals, calculated at the hospital purchase price, the same below; MAT (Moving Annual Total): represents the sum of the indicators rolling forward one year from the current month; Bn: represents one billion) Figure 1 National -Hospital Drug Market - Sales Scale Secondary Hospitals vs Tertiary Hospitals: Sales of secondary and tertiary hospitals in 2022Q1 both declined year-on-year , and the structure remains stable; the sales of tertiary hospitals in 2022Q1 exceeded 157 .
Both secondary and tertiary hospitals saw a decline in sales in the quarter, with year-on-year growth rates of -4% and -5%, respective.
Figure 2 National - secondary & tertiary hospitals - sales proportion trend and sales growth rate (%) Chemical drugs (including biological products) VS Chinese patent medicines: The proportion of Chinese patent medicines has steadily increased, and 2022Q1 showed positive growth due to the attributes of traditional Chinese and Western medicines Look, the sales scale of chemical drugs (including biological products) has continued to decline in the past two quarters, and the year-on-year growth rate of sales in 2022Q1 is -
Different from chemical drugs, under the background of the state's vigorous support for the high-quality development of the Chinese medicine industry, the sales scale of Chinese patent medicines continued to increase, and this quarter maintained a positive year-on-year growth (+6.
Figure 3 National chemical drugs (including biological products) & Chinese patent medicines - sales ratio trend and year-on-year growth rate (%) Regional performance of hospital drug market: Guangdong Province ranks first in weight, Inner Mongolia and Hubei have outstanding growth, and the scale is double From a regional perspective, the hospital drug market in Guangdong Province ranks first in terms of scale, and the growth rate is slightly lower than the national level (4% vs 6%); Inner Mongolia and Hubei Province MAT2022Q1 sales increased rapidly, with double-digit growth year-on-ye.
Among the 30 provinces and cities, the hospital market in seven provinces, Jiangsu, Zhejiang, Heilongjiang, Yunnan, Guizhou, Gansu and Hainan, has shru.
Figure 4 National-Hospital Drug Market-Scale and Growth Rate of 30 Provinces and Cities (MAT2022Q1)
